Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.

Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M.

J Thromb Haemost. 2013 Mar;11(3):481-90. doi: 10.1111/jth.12114.

2.

Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.

Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN.

Pediatr Blood Cancer. 2013 Oct;60(10):1676-82. doi: 10.1002/pbc.24612. Epub 2013 Jun 1.

PMID:
23729372
3.

A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab.

Clark WF, Rock G, Barth D, Arnold DM, Webert KE, Yenson PR, Kelton JG, Li L, Foley SR; members of Canadian Apheresis Group.

Br J Haematol. 2015 Jul;170(2):208-17. doi: 10.1111/bjh.13408. Epub 2015 Apr 8.

PMID:
25855259
4.

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.

Hie M, Gay J, Galicier L, Provôt F, Presne C, Poullin P, Bonmarchand G, Wynckel A, Benhamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, Hamidou M, Vernant JP, Veyradier A, Coppo P; French Thrombotic Microangiopathies Reference Centre.

Blood. 2014 Jul 10;124(2):204-10. doi: 10.1182/blood-2014-01-550244. Epub 2014 May 28.

5.

A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.

Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ.

Blood. 2011 Aug 18;118(7):1746-53. doi: 10.1182/blood-2011-03-341131. Epub 2011 Jun 2.

6.

Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.

Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, Scalzulli PR, Paolini R, Marcenò R, Remuzzi G, Galbusera M.

Thromb Haemost. 2009 Feb;101(2):233-8.

PMID:
19190804
7.

Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.

Goyal J, Adamski J, Lima JL, Marques MB.

J Clin Apher. 2013 Dec;28(6):390-4. doi: 10.1002/jca.21289. Epub 2013 Jul 16.

PMID:
23857472
8.

Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.

Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grünfeld JP.

Blood. 2005 Sep 15;106(6):1932-7. Epub 2005 Jun 2.

9.

[Successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura refractory to plasma exchange].

Koshino M, Kudou D, Okoshi Y, Obara N, Simizu S, Mukai HY, Suzukawa K, Hasegawa Y, Kojima H, Nagasawa T, Chiba S.

Rinsho Ketsueki. 2010 Feb;51(2):127-31. Japanese.

PMID:
20379104
10.

Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature.

Ling HT, Field JJ, Blinder MA.

Am J Hematol. 2009 Jul;84(7):418-21. doi: 10.1002/ajh.21439. Review.

11.

Rituximab as prophylaxis in chronic relapsing thrombotic thrombocytopenic purpura: a case report and review of the literature.

Montoya RC, Poiesz BJ.

Blood Coagul Fibrinolysis. 2012 Jun;23(4):338-41. doi: 10.1097/MBC.0b013e3283529184.

PMID:
22498981
12.

Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature.

Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B.

J Clin Apher. 2008;23(5):151-6. doi: 10.1002/jca.20172. Review.

PMID:
18712712
13.

Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports.

Iioka F, Shimomura D, Ishii T, Maesako Y, Ohgoe K, Nakamura F, Matsuo S, Ohno H.

Int J Hematol. 2012 Oct;96(4):506-12. doi: 10.1007/s12185-012-1162-2. Epub 2012 Aug 10.

PMID:
22878941
14.

[Rituximab for managing refractory thrombotic thrombocytopenic purpura: a report of three cases].

Yamanouchi J, Hato T, Miyoshi K, Kobayashi S, Azuma T, Hasegawa H, Yasukawa M.

Rinsho Ketsueki. 2013 Feb;54(2):205-9. Japanese.

PMID:
23470828
15.

Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.

Kameda T, Dobashi H, Kittaka K, Susaki K, Yamaoka G, Arai K, Tokuda M, Ishida T.

Clin Rheumatol. 2007 Dec;26(12):2159-2162. doi: 10.1007/s10067-007-0631-0. Epub 2007 Jun 12.

PMID:
17562094
16.

Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.

Jayabose S, Dunbar J, Nowicki TS, Tugal O, Ozkaynak MF, Sandoval C.

Pediatr Hematol Oncol. 2011 Mar;28(2):167-72. doi: 10.3109/08880011003739414. Epub 2010 May 14.

PMID:
20469972
17.

Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).

Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, Schechter GP.

Am J Hematol. 2004 Oct;77(2):171-6.

18.
19.

Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays.

McDonald V, Liesner R, Grainger J, Gattens M, Machin SJ, Scully M.

Blood Coagul Fibrinolysis. 2010 Apr;21(3):245-50. doi: 10.1097/MBC.0b013e32833679cb.

PMID:
20083997
20.

Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.

Elliott MA, Heit JA, Pruthi RK, Gastineau DA, Winters JL, Hook CC.

Eur J Haematol. 2009 Oct;83(4):365-72. doi: 10.1111/j.1600-0609.2009.01292.x. Epub 2009 Jun 8. Review.

PMID:
19508684

Supplemental Content

Support Center